Effects of transcutaneous electrical nerve stimulation (TENS) on arterial stiffness and blood pressure in resistant hypertensive individuals: study protocol for a randomized controlled trial by José Fernando Vilela-Martin et al.
STUDY PROTOCOL Open Access
Effects of transcutaneous electrical nerve
stimulation (TENS) on arterial stiffness and
blood pressure in resistant hypertensive
individuals: study protocol for a
randomized controlled trial
José Fernando Vilela-Martin1*, Luiz Tadeu Giollo-Junior1, Gaspar Rogério Chiappa2, Gerson Cipriano-Junior3,
Paulo José Cardoso Vieira4, Fábio dos Santos Ricardi1, Manoel Ildefonso Paz-Landim1, Days Oliveira de Andrade1,
Elizabeth do Espírito Santo Cestário1, Luciana Neves Cosenso-Martin1, Juan Carlos Yugar-Toledo1
and José Paulo Cipullo1
Abstract
Background: Resistant hypertension (RH) treatment requires an adequate and intense therapeutic approach.
However, the results are not always satisfactory despite intensive treatment. Of the different pathophysiological
mechanisms involved in the pathogenesis of RH, sympathetic overstimulation and therapies that block the
sympathetic system have been widely studied. These approaches, however, are invasive and expensive.
Another possible approach is by transcutaneous electrical nerve stimulation (TENS), a noninvasive method that
modulates activity by using low-frequency transcutaneous electrical stimulation to inhibit primary afferent
pathways. Thus, the current study will evaluate the effect of applying TENS in the cervicothoracic region of
subjects with RH and will seek to develop a new low-cost and readily available therapy to treat this group of
hypertensive individuals.
Methods/design: This is a randomized, single blind (subject), parallel-assignment study controlled with a
sham group and including participants aged 40 to 70 years with resistant hypertension. The trial has two
arms: the treatment and control (sham group). The treatment group will be submitted to the stimulation
procedure (TENS). The sham group will not be submitted to stimulation. The primary outcomes will be a
reduction in the peripheral blood pressure and adverse events. The secondary outcomes will be a reduction
the central blood pressure. The study will last 30 days. The sample size was calculated assuming an alpha
error of 5 % to reject the null hypothesis with a statistical power of 80 %, thereby resulting in 28 participants
per group (intervention versus sham).
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Discussion: In recent decades, RH has become very common and costly. Adequate control requires several drugs, and
in many cases, treatment is not successful. Sympathetic nervous system inhibition by renal denervation and central
inhibition have significant effects in reducing BP; however, these treatments are costly and invasive. Another type of
sympathetic nervous system inhibition can also be noninvasively achieved by electric current. Therefore, the application
of TENS may be a new therapeutic option for treating resistant hypertensive individuals.
Trial Registration: Clinical Trials NCT02365974
Keywords: Arterial stiffness, Resistant hypertension, Sympathetic system, Blood pressure, Transcutaneous electrical
nerve stimulation
Background
Hypertension in the context of cardiovascular disease
In Brazil, cardiovascular diseases (CVD) accounted for
30 % of deaths in 2008, with hypertension alone affecting
more than 36 million people [1]. In the United States,
this figure is even higher, as approximately 80 million
Americans have hypertension [2].
As one of the main risk factors for the development of
CVD, hypertension is the starting point of cardiovascular,
cerebrovascular, and renal impairment. In most cases, by
the time there is a manifestation, this disease, although still
manageable, is irreversible. The main risk factors associated
with hypertension are smoking, physical inactivity, stress,
alcohol consumption, age, obesity, and an unhealthy diet
[3], all of which can alter the integrity of the vascular endo-
thelium and lead to a number of complications.
Currently, a broad therapeutic arsenal is available for the
treatment of hypertension. Nonetheless, sometimes hyper-
tension becomes difficult to control due to varying situa-
tions, thereby characterizing resistant hypertension (RH),
which requires a more intensive therapeutic approach. RH
is a condition in which the blood pressure (BP) remains
above the recommended target even when treated with the
maximum tolerated doses of three antihypertensive drugs
with synergistic actions, including a diuretic. A condition
exists that is known as controlled resistant hypertension,
which is defined as high BP that is controlled using four
antihypertensive drugs [4]. Although the exact prevalence
of RH has not yet been precisely established, this state is es-
timated to occur in 12–15 % of the hypertensive population
[5]. The risk factors associated with RH are similar to those
of hypertension; however, it is more common in elderly pa-
tients; females; Blacks; obese patients; physically inactive
patients; and those with left ventricular hypertrophy, dia-
betes mellitus, chronic renal disease, metabolic syndrome,
and high sodium intake [4].
Hypertension and inflammatory markers
The long-term effect of RH on the vascular system can be
catastrophic. Currently, vascular abnormalities are known
to exist early in the development of hypertensive diseases
and may manifest as severe endothelial dysfunction.
Endothelial dysfunction is considered an early marker
of vascular complications. It participates in the patho-
physiology of atherogenesis, which occurs in one of the
first stages of arterial disease [6, 7] as a result of risk fac-
tors that promote oxidative stress and nitric oxide (NO)
inactivation [8]. Endothelial dysfunction involves several
functional changes: impaired endothelium-dependent
vasodilation, changes in the endothelial barrier function,
inflammatory activation, and stimulation of coagulation
[9]. Proinflammatory changes seem to be involved in the
development of hypertension and in many other situa-
tions, including aging, diabetes, dyslipidemia, smoking,
and obesity [10–13]. These changes are characterized by
a series of highly specific and essentially inflammatory,
cellular, and molecular responses that lead to endothelial
injury. Environmental factors such as salt intake and
psychosocial stress may contribute to the activation of
systems that participate in the pathogenesis and progres-
sion of hypertension. Moreover, both the sympathetic
nervous and renin-angiotensin-aldosterone systems have
very important roles, as there are correlations between
the activation of these systems and increased inflamma-
tory activity in hypertensive subjects. Thus, hypertension
seems to be associated to inflammatory disorders [13].
The inflammatory process is characterized by infiltration
of macrophages and T lymphocytes in the endothelium.
Activated lymphocytes and macrophages release a var-
iety of inflammatory mediators such as cytokines, adhe-
sion molecules, and matrix metalloproteinases (MMPs),
resulting in increased inflammatory cell recruitment, the
migration and proliferation of endothelial cells, platelet
aggregation, and the release of free radicals [11, 14].
Several inflammatory markers, such as proinflammatory
cytokines, interleukins (IL-1β, IL-6, IL-8, IL-18), and
tumor necrosis factor (TNF-α) related to activated mono-
cytes, have been identified in these situations. Elevated ex-
pressions of intercellular adhesion molecule-1 (ICAM-1)
in endothelial cells [11, 15, 16] and highly sensitive C-
reactive protein (hsCRP) have also been found. Recent
studies show that cardiovascular risk is twice as high
in patients with elevated hsCRP compared to patients
with lower values. The hsCRP also has an effect on
Vilela-Martin et al. Trials  (2016) 17:168 Page 2 of 13
the endothelial surface as the migration and adhesion
of monocytes increases, causing the synthesis of
chemotactic factors due to the secretion of other pro-
inflammatory factors, such as TNF-α, IL-6, and IL-8
[13, 17]. In addition to proinflammatory cytokines,
other cytokines with anti-inflammatory activity, such
as IL-10, are present.
In animal studies, IL-10 has demonstrated protective
roles against the stability and formation of atherosclerotic
lesions. Some clinical studies have shown that patients
with acute coronary syndrome have reduced IL-10 levels
compared to stable patients, raising the possibility that
low levels of IL-10 may be related to atherosclerotic
plaque instability [18].
Vascular endothelial dysfunction also promotes inflam-
mation by inducing the production of vasoconstrictor
agents, adhesion molecules, and growth factors, includ-
ing angiotensin II (Ang II). Ang II, one of the end prod-
ucts of the renin-angiotensin system (RAS), is actively
involved in the pathogenesis/pathophysiology of hyper-
tension. It may be responsible for triggering endothelial
dysfunction and vascular inflammation by inducing oxi-
dative stress, a fact that results in the release of inflam-
matory mediators and in cell growth [12, 13, 18, 19].
Some studies have demonstrated that Ang II increases
the expressions of IL-6, IL-8, IL-18, and the monocyte
chemoattractant protein (MCP-1), the last of which is
the main regulator of leukocyte recruitment to the vas-
cular wall. In addition, Ang II stimulates the expression
of ICAM-1 and the infiltration of macrophages inde-
pendently of the increase in BP [19, 20].
The role of Ang II as a proinflammatory mediator of
vascular injury is supported by the protective anti-
inflammatory effects of RAS inhibitors. Among other
effects, RAS inhibitors have properties that result in an-
tithrombotic and fibrinolytic actions. The thrombogenic
status mainly results from a high concentration of plas-
minogen activator inhibitor (PAI-1), which leads to an
excessive accumulation of fibrin inside vessels, a situ-
ation that contributes to vascular events [14]. Thus,
PAI-1 is considered an important regulator of thrombo-
genesis; increased thrombogenesis can increase the risk
of atherothrombotic events and promotes the progres-
sion of vascular disease [21].
Fibrinogen, an acute phase protein, and cytokines are
also directly related to vascular disease [22]. Prospective
studies on healthy subjects demonstrated a direct and
independent association between the plasma fibrinogen
levels and the risk of coronary and cardiovascular events
and mortality [16].
As previously mentioned, vascular inflammation and
oxidative stress play a crucial role in the pathogenesis
of vascular injury mediated by Ang II. Recently,
angiotensin-converting enzyme 2 (ACE-2) was
identified as having a pleiotropic effect on Ang II,
resulting in the neutralization of its proinflammatory
and pro-oxidant actions via receptors. Interestingly,
the Ang II type-1 receptor blockers may increase
ACE-2 expression and activity, thereby reducing car-
diovascular and oxidative damage [23].
MMPs are responsible for the degradation of extracel-
lular matrix proteins, breaking them down into their
specific peptide bonds, including the cells of the vascular
smooth muscle, endothelium, fibroblasts, and inflamma-
tory cells [24–26]. The interaction of MMPs with their
endogenous tissue inhibitors (MMP tissue inhibitors -
TIMPs) is important among the factors that regulate
MMP activity [27–29]. Under physiological conditions, a
balance exists in the ratio of MMPs and TIMPs. How-
ever, during pathological processes such as hypertension,
an imbalance occurs that leads to excessive degradation
of extracellular matrix proteins [28] and, consequently,
to pathological vascular remodeling. Among these pro-
teolytic enzymes, MMP-9 has an important role in car-
diovascular diseases, including atherosclerosis, coronary
artery disease, vascular aneurysms, and hypertension
[30–36]. Studies suggest that increases in MMP-9 activ-
ity are associated with increased arterial stiffness not
only in patients with isolated systolic hypertension but
also in young individuals without comorbidities [34, 36].
Notwithstanding these reports, studies are scarce that
compare MMP levels with arterial stiffness markers in
populations with different BP levels.
The aforementioned biochemical changes have a dir-
ect relationship with high BP, endothelial dysfunction,
and increased vascular stiffness in RH patients, as is
demonstrated by reduced flow-mediated vasodilation
and increased pulse wave velocity (PWV), which result
in higher central BP levels (CBP) [37].
Central hemodynamics, sympathetic inhibition and
hypertension
The CBP has a predictive value in the risk stratification
of cardiovascular morbidity and mortality as demon-
strated by the CAFE (Conduit Artery Function Evalu-
ation) study. This study showed different effects on the
CBP of groups treated with amlodipine and atenolol
even though reductions in peripheral arterial pressure
were similar. This difference has been suggested to be
responsible for the favorable cardiovascular outcomes
in the amlodipine group of the ASCOT study (Anglo-
Scandinavian Cardiac Outcomes Trial), which demon-
strated the importance of CBP control in relation to
peripheral BP and how it can be influenced by certain
drug therapies [38].
The CBP is directly influenced by arterial stiffness; the
arteries, especially the aorta and carotid, are estimated
to stiffen by about 10 to 15 % in men and 5 to 10 % in
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women each decade [39]. Arterial stiffness is a major de-
terminant for the increase in the pulse pressure (PP)
and CBP, variables considered risk predictors of myo-
cardial infarction, stroke, and heart failure. In addition,
higher cardiovascular morbidity and mortality have
been associated with increased CBP, especially in hyper-
tensive diabetics, the elderly, and chronic renal disease
patients [40, 41]. Thus, advanced age and high BP are
the two most important variables for increased arterial
thickness and, consequently, arterial stiffness.
The influence of arterial stiffness on the CBP explains
why the pulse wave, generated in every left ventricular
ejection period, propagates cyclically throughout the ar-
terial tree to the peripheral arteries. Changes in the im-
pedance and structural or geometric discontinuity of the
arterial tree along its path generate reflected waves that
move backwards into the ascending aorta and to the
heart (backward wave). Therefore, the CBP is the sum of
the anterograde and retrograde (reflected wave) compo-
nents [42, 43]. Wave propagation is amplified from the
central aorta to the peripheral arteries. That is, the amp-
litude of the pressure wave will be greater in peripheral
arteries than in the central arteries, which explains the
increased pressure in the brachial artery compared to
the aorta (central) in younger individuals (the CBP is
about 10 to 20 mmHg lower than the peripheral BP).
With aging, a loss occurs in arterial elasticity, increasing
both the arterial stiffness and the PWV. Increased PWV
causes a faster return of the reflected pulse wave with
early overlap of the reflected wave during systole (unlike
what happens in healthy young people when the
reflected wave returns later in systole). This leads to an
increase in the systolic pressure and elevation in central
PP (PP amplification), which, in turn, increases the after-
load on the left ventricle and reflects an increase in the
CBP, which almost equals the peripheral BP [43, 44].
This increase in the CBP caused by the reflection of
waves is known as the augmentation index (AIx). Hence,
the AIx is an alternative index derived from the analysis
of the central aortic pressure curve and quantifies the ef-
fect of reflected waves [45–47]. It has the advantage of
taking into account the time of anterograde and retro-
grade waves, which are the main determinants of CBP.
Currently, nonpharmacological therapeutic methods are
being used to treat RH. These are invasive, require long-
term follow up to monitor the results and may cause
unwanted complications during and after the procedure,
besides being expensive. Examples of these methods are
denervation or ablation of the renal sympathetic ganglia
and chronic carotid baroreflex stimulation [48]. Both these
techniques have generated good results in the reduction
of peripheral BP by improving vasomotor tone related
to sympathetic suppression; however, similar reductions
in BP were reported for treatment and placebo groups
[48, 49]. Thus, the identification of new noninvasive thera-
peutic approaches to control RH is essential. Transcutane-
ous electrical nerve stimulation (TENS) may be a new,
easy to apply, reproducible, and inexpensive technique for
this purpose. TENS is capable of inhibiting primary affer-
ent pathways using low-frequency electrical pulses gener-
ated by electrodes attached to the skin, which cause local
numbness and thus inhibit pain [50, 51]. In addition to
the analgesic effects, electrical stimulation has been shown
to enhance a local vasodilator effect, which may contrib-
ute to reducing BP and prevent ischemia [52]. Among the
mechanisms that might explain this anti-ischemic
action are the inhibition of sympathetic segmental
vasoconstriction, release of vasodilatory peptides from
sensory neurons, and the pump effect of muscle
contractions [53–56]. Other favorable effects have been
observed on applying TENS in the cervicothoracic gan-
glion region. The cervicothoracic ganglion or stellate
ganglion, whose predominant action is sympathetic ac-
tivity, is a confluence of nerves located in the posterior
cervical region at the junction of the lower and upper
thoracic cervical ganglia [53–58].
Mannheimer et al. demonstrated that low-frequency
electrical stimulation applied to the suprathoracic
lymph node region produced an anti-ischemic effect by
reducing myocardial oxygen demand due to the reduc-
tion in the afterload resulting from a reduction in BP
[53]. This response, which is hypothetically based on
the observed reduction in epinephrine and norepineph-
rine levels, may involve a reduction in sympathetic ner-
vous system activation [53, 57]. In turn, Silva et al.
observed that TENS applied to the suprathoracic gan-
glion region during exercise might be associated with
decreased peripheral and central BP in healthy young
people, a response indicated by significant changes in
heart rate variability [58].
Given the scarcity of publications in the scientific lit-
erature, this innovative work will study the effects of the
application of TENS in the suprathoracic lymph node
region to reduce peripheral BP and CBP in RH patients.
Rationale
Due to the high incidence of cardiovascular morbidity
and mortality caused by RH, the introduction of new,
more effective, highly specific, and noninvasive thera-
peutic approaches that are reproducible and less costly
from a financial point of view are needed.
Research question
The following research questions will be explored:
– Does TENS constitute a new therapeutic option
in the reduction of peripheral blood pressure of
patients with resistant hypertension?
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– Does TENS constitute a new therapeutic option
in the reduction of central pressure of resistant
hypertensive patients?
– Does TENS reduce arterial stiffness measurement
parameters?
– Can TENS positively influence metabolic
disorders that involve the progression of arterial
stiffness?
Objectives
The research objectives of this study are as follows:
1) To evaluate the effectiveness of TENS as
antihypertensive therapy in RH patients
2) To assess the peripheral and central BP before and
after the use of TENS
3) To evaluate the behavior of arterial stiffness by
measuring the AIx and PWV before and after the
use of TENS
4) To observe the biochemical changes,
inflammatory markers, and the participation of




The present trial (clinicaltrials.gov identifier: NCT023
65974, registered on 8 February 2015) will be a random-
ized, open-label, parallel-assignment study controlled
with a sham group. All patients who participate in the
research will sign informed consent forms. The project
design, approved by the Research Ethics Committee of
FAMERP, São Paulo, Brazil, which is accredited by the
Office of Human Research Protections as an Institu-
tional Review Board (CAAE n° 07606212.5.0000.5415, n°
94.248/2012) (Additional file 1), will comply with the
following described criteria.
Inclusion criteria
The inclusion criteria are as follows:
a) RH patients taking at least three antihypertensive
drugs at full doses, one of which is preferably a
thiazide diuretic
b) Age between 40 and 70 years
Exclusion criteria
The exclusion criteria are as follows:
a) Use of a cardiac pacemaker
b) Cardiac electrical conduction abnormalities
evidenced by ECG or stress test (ergometry)
c) Dermatological abnormalities at the site of the
application of TENS
d) Uncontrolled diabetes in patients using oral
hypoglycemic agents or insulin with glycated
Hb ≥ 7.5 %
e) Secondary hypertension
f ) Patients who do not adhere to the lifestyle changes
recommended by their physician such as low-
sodium diet and weight loss
g) Moderate to severe cervical-thoracic scoliosis
h) Obesity with body mass index (BMI) ≥ 35 kg/m2
Random allocation
A computer-validated software program (Random Allo-
cation) will be used for the random allocation. The study
coordinator will organize and number the envelopes,
which will be allocated in order of patient enrollment.
The professional responsible for the Endo-PAT proced-
ure and evaluation of arterial stiffness parameters will be
blinded.
Interventions
TENS will be applied in the cervicothoracic ganglion re-
gion in the active comparator group, and the sham
group will not be submitted to transcutaneous electrical
stimulation. Figure 1 shows a flowchart of the selection
of participants and interventions.
Randomization and follow‐up
Protocol
Patients will be divided into two groups: treatment and
control (sham group). The sham group will be submitted
to the procedure to fit the stimulation equipment. How-
ever, these patients will not be submitted to stimulation.
Both groups will undergo a physical examination at the
start and end of the study period to determine anthropo-
metric variables. The BMI, defined as the weight (kg)
divided by the patient’s height squared (m2), will be cal-
culated. The height will be determined in centimeters
using a measuring tape while the individual stands in
bare feet. Individuals with a BMI < 25 kg/m2 will be clas-
sified as normal, overweight as a BMI between 25 and
30 kg/m2, and obese as a BMI ≥ 30 kg/m2. The waist cir-
cumference will be measured using a measuring tape at
half the distance between the iliac crest and the lower
costal margin. Patients will undergo the following tests
before and after the end of the 4-week study period: 24-
h ambulatory blood pressure monitoring (ABPM), 24-h
dynamic electrocardiography, continuous measurement
of beat-to-beat BP, endothelial function measurement
(Endo-PAT 2000), and radial artery applanation tonom-
etry (AT). Table 1 shows a summary of the key practical
aspects of the study with all follow-up visits and
requested exams, and Fig. 1 represents the flowchart of
the study.
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Ambulatory blood pressure monitoring
ABPM will be performed using the Mobil-O-Graph
monitoring device (I.E.M. Gmb, Stolberg, Germany)
[59]. Monitoring requires patients to maintain their nor-
mal daily activities with the BP being measured automat-
ically at 30-minute intervals for an entire 24-h period
according to the technical norms of the 5th Guidelines
on Ambulatory Blood Pressure Monitoring [60]. The fol-
lowing parameters will be measured and evaluated over
24 h: systolic (SBP) and diastolic BP (DBP), PP, central
systolic and diastolic aortic pressure, central PP, AIx,
PWV, cardiac output, and peripheral vascular resistance.
The SBP and DBP will be obtained by ABPM with
the mean values for the 24-h period, daytime, and
nighttime being considered for analysis. RH patients
with mean BP values of ≥ 130 × 80 mmHg over 24 h, ≥
135 × 85 mmHg during wakefulness, and ≥ 120 × 70 mmHg
when asleep will be considered. PP will be calculated
during the periods (24 h, daytime, and night) using
the formula PP = SBP - DBP. The normal nocturnal
dip will be defined as a drop >10 % in SBP from
wakefulness to the period of sleeping.
24-hour electrocardiographic monitoring
The assessment of the effects of the inhibition of sympa-
thetic nerve activity on the cardiovascular system will be
by 24-h dynamic electrocardiography (Holter System -
Cardios-Light/Cardios) in accordance with the Guide-
lines for the Evaluation and Treatment of Patients with
Cardiac Arrhythmias [61]. The Holter System will be at-
tached to the patient early in the morning to perform a
continuous recording of ambulatory electrocardio-
graphic signals over 24 h. The electrode attachment sites
will be shaved and cleaned to reduce skin impedance.
During the monitoring period, the patients should
continue their normal daily activities. All data will be
recorded on a digital recorder, with subsequent ana-
lysis being carried out by trained professionals. Re-
cordings will be made using three bipolar precordial
leads; the CM5 lead is very sensitive in the diagnosis
Fig. 1 Flowchart of study
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of changes in heart rhythm and for detecting myocar-
dial ischemia [61, 62].
Evaluation of sympathetic activity (continuous
measurement of beat-to-beat blood pressure)
The continuous measurement system of beat-to-beat BP
(NEW Finapres® - Finapres Medical System/Medical Bio-
link) will be used to evaluate the sympathetic activity.
Patients will be placed in a quiet room with controlled
temperature (22 °C), without having ingested any kind of
natural or drug stimulant and without pain or a full
bladder [63, 64]. Before the examination, the patient
must remain seated and at rest for 15 min. After place-
ment of the cuffs, the arms will be fully supported at the
xiphoid process, and the BP will be recorded for 5 min.
Evaluation of endothelial function
The peripheral endothelial function will be assessed
noninvasively by measuring the reactive hyperemia of
the vessel using the Endo-PAT system (peripheral arterial
tonometry - Endo-PAT 2000; Itamar Medical, Caesarea,
Israel) [65]. Patients will be instructed to appear for this
exam after 12-h overnight fasting, including from any kind
of medicine. The temperature of the examination room
will be maintained between 21 °C and 24 °C, and tight
clothing, watches, bracelets, and rings that might interfere
with blood flow to the arms will be removed. During at
least 15 min, the patients will remain sitting or lying in
the examination room to ensure a relaxed cardiovascular
status [65–67].
A pressure cuff is placed on one arm (study arm),
whereas the other serves as a control (control arm). The
device, comprising a pneumatic plethysmograph, is
placed on the tip of each index finger, and a uniform
pressure is applied to the distal digital surface allowing
the measurement of changes in the pulse volume. The
insufflation pressure of the digital device is electronically
set at 10 mmHg below the DAP or at 70 mmHg. After a
10-min regulation period, the BP cuff is inflated to
60 mmHg above systolic pressure or to 200 mmHg for
Table 1 Key practical aspects of the study with all the clinical visits and the requested exams
Visits Screening 1st week 2nd week 3rd week 4th week
Weeks −1 1 2 3 4
Informed consent X
Inclusion and exclusion criteria X X
Medical history X
Medical evaluation/physical examination (BP measure) X X X X X
Randomization X
Application of TENS (3x/week) X X X X
Creatinine X X
Fasting glucose X X
Glycated hemoglobin X X
Potassium X X
Uric acid X X
Insulin X X
Total cholesterol X X
HDL-c X X
Triglycerides X X
Urinary sodium X X
Urinary potassium X X
Microalbuminuria X X
GFR estimation X X
Specific biochemistry tests X X
Ambulatory blood pressure monitoring X X
24-h electrocardiographic monitoring X X
Evaluation of sympathetic activity X X
Evaluation of endothelial function X X
Evaluation of arterial stiffness X X
BP Blood pressure, TENS transcutaneous electrical nerve stimulation, HDL-c high-density lipoprotein cholesterol, GFR glomerular filtration rate
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5 min. The device continues to record for 10 min after
the cuff is deflated. The absence of residual pulsatility is
monitored in the occlusion period. The hyperemia
after the period of occlusion stimulates endothelium-
dependent vasodilation, causing an increase in the
amplitude of the digital pulse. Changes in the pres-
sure signals are filtered, amplified, recorded electronically,
and analyzed using an automated computerized algorithm
(Itamar Medical). The change from the baseline measure-
ment is defined as the reactive hyperemia index (RHI),
which will reflect, in part, the vasodilator function of the
digital microcirculation. Endothelial dysfunction is de-
fined as a mean value of 2.34 ± 0.33 less two standard
deviations of 20 asymptomatic, healthy control sub-
jects with no history of cardiovascular disease and
without major risk factors (RHI ≤ 1.68) [67].
Evaluation of arterial stiffness
The arterial stiffness will also be evaluated by AT of the
radial artery, as suggested by taking an average of three
measurements after the pressure is stabilized. The
HEM9000 AI device (OMRON Healthcare, Co. Kyoto,
Japan) will be used for this exam.
The AT examination will be performed in a quiet con-
trolled environment (temperature between 21 °C and
24 °C) after the patient has rested for at least 5 min
while sitting with the legs uncrossed, the bladder empty,
and away from acute stressors. The patient will not have
smoked at all for at least 30 min or ingested alcohol.
The OMROM AT equipment uses a radial ultrasonic
transducer and cuffs with the correct size for the arm
circumference, as recommended by the guidelines to
evaluate BP [1].
Application of TENS
TENS will be applied in the cervicothoracic ganglion re-
gion located between the C7 and T4 vertebral processes
for 40 min three times weekly for a total of 4 weeks.
Electrostimulators (Endomed 684, Enraf Noniuns,
Rotterdam, Netherlands) with two 80-Hz output channels
at a pulse width of 150 μs will be used for the appli-
cation of TENS. The intensity in milliamps (mA) will
be adjusted depending on the sensitivity of each individual
patient. This electrical stimulus has a high-frequency
current that will cause mild local paresthesia without
causing pain or unpleasant sensations. The intensity will
be increased from zero until the perceived sensation
reaches the maximum sensory threshold without pain or
discomfort or involuntary muscle contractions. The 5 × 5-
cm self-adhesive electrodes (Valutrode mark) are attached
to the patient after marking the correct location using
a dermatographic pencil and cleaning the skin. The ar-
rangement thereof will be parallel on each side of the
C7 (channel 1) and T4 (channel 2) vertebral spinous
processes (Fig. 2) [58].
General biochemistry assessment
Biochemical tests will be performed at two time points,
before and after the 4-week study period, and include
blood sugar, glycated hemoglobin, total cholesterol (TC),
high-density lipoprotein cholesterol (HDL-C), triglycer-
ides (TG), creatinine, potassium, uric acid, and plasma
insulin levels.
Blood sugar, TC, HDL-C, and TG levels will be deter-
mined by colorimetry after fasting for 12 h using a RXL
Dimension device with the Dade Behring reagent. Diag-
nosis of diabetes mellitus (DM) will be established by
patient history, the use of hypoglycemic drugs, and
measurement of the serum glucose [68]. The LDL-C
fraction will be calculated using the formula LDL-C =
TC - HDL-C - TG/5 (for TG < 400 mg/dL) [69]. Add-
itionally, the electrochemiluminescence method will be
used to measure plasma insulin (immunoassay for the
in vitro quantitative determination of human insulin in
serum and plasma using the Elecsys 1010/2010 immuno-
assay and E170 modular analytics analyzers by Roche).
The homeostasis model assessment of insulin resistance
(HOMA-IR) index will be applied after obtaining blood
sugar and insulin levels in order to determine insulin re-
sistance and the functional capability of the pancreatic
beta cells. Insulin resistance will be characterized when
this ratio exceeds 2.71 [70]. The HOMA-IR index is
calculated using the following formula:
Fig. 2 Diagram showing the location for application of the
transcutaneous electrical nerve stimulation (TENS)
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HOMA‐IR :
Fasting insulin McU=mLð Þ  fastingglucose mmol=Lð Þ
22:5
:
In order to convert the glucose concentration to
mmol/L it is necessary to multiply the value in mg/dL
by 0.0555.
Measurement of serum creatinine will be performed
by a standardized enzyme-kinetic biochemical test and
will be considered high when serum creatinine is >
1.4 mg/dL [71, 72].
Urinary sodium and potassium levels (mEq/L) will be
evaluated by flame photometry. Urinary sodium and po-
tassium levels excretion will be calculated by multiplying
the urinary sodium and potassium concentrations in
mEq/L by the 12-h urine volume [73]. Microalbuminuria
will also be evaluated. To evaluate microalbuminuria,
the urinary albumin-to-creatinine ratio (UACR) will be
obtained from urine samples collected in the morning.
Urine creatinine will be calculated using a colorimetric
method, and albuminuria will be determined using the
nephelometric method. The glomerular filtration ratio
(GFR) will be estimated using the modification of diet in
renal disease (MDRD) formula: GFRMDRD (mL/min/
1.73 m2) = 186 (serum creatinine)−1.154 × (age)−0.203 × (0.742
if female) × (1.212 if black) [74].
Specific biochemistry tests
Specific biochemical tests will be considered (Table 2):
serum aldosterone (AS); plasma renin activity (PRA); highly
sensitive C-reactive protein (hsCRP); metalloproteinase 9
(MMP-9); tissue inhibitors of metalloproteinase (TIMP-1
and TIMP-2); nitrites and nitrates; interleukin-1, 6, 8, 10,
and 18 (IL-1, IL-6, IL-8, IL-10 and IL-18); TNF-α, thromb-
oxane B2 (TXB2); fibrinogen; intercellular adhesion
molecule-1 (ICAM-1); plasminogen activator inhibitor
(PAI-1); angiotensin converting enzyme (ACE); and angio-
tensin II (Ang II).
To evaluate the hsCRP, MMP-9, TNF-α, AS, PRA,
TIMPs-1 and −2, nitrites and nitrates, IL-1, IL-6, IL-8,
IL-10, IL-18, thromboxane B2, and fibrinogen levels,
plasma samples will be obtained after centrifugation at
3500 rpm and 4 °C for 15 min immediately after collec-
tion and then stored at −80 °C for later analysis. The IL-
1, IL-6, IL-8, IL-10, IL-18, TNF-α, MMP-2 and −9, ACE,
and Ang II will be measured using the ELISA technique
(R & D systems, Minneapolis, MN, USA) according to
the manufacturer’s instructions and as described in a
previous study [75]. The hsCRP is determined by a
highly sensitive assay with a BN II nephelometer (Dade
Behring, Marburg, Germany). The multiplex method will
be used to measure the PAI-1 and ICAM-1 inflamma-
tory mediators [14]. Plasma concentrations of tissue
inhibitors (TIMP-1 and −2) will be measured using a
commercially available enzyme-linked immunosorbent
assay (R & D Systems, Minneapolis, MN, USA) accord-
ing to the manufacturer’s instructions.
The routine PRA assay available today is based on the
determination of plasma angiotensin I generated in vitro
by the proteolytic action of renin on its substrate: angio-
tensinogen under predetermined conditions of time and
temperature. Blood samples should be collected and
maintained with special care: (1) in iced syringes and
tubes, (2) using EDTA as a proteolysis inhibitor (angio-
tensinase), (3) separating the plasma in a refrigerated
centrifuge no more than 30 min after each collection,
and (4) separating and storing the plasma at −20 °C or
less (ideally at −70 °C) until the time of the assay. As the
PRA levels fluctuate in response to posture, diet, and hy-
dration (in parallel with the aldosterone system), refer-
ence values exist for the various conditions, but most
laboratories require that the patient has fasted and
rested lying down for at least 30 min before the collec-
tion of baseline samples [76].
A commercial kit (Cayman Chemical Co. Ann Arbor,
MI, USA) will be used under controlled conditions to
measure the total nitrite and nitrate concentrations in
the biological fluids and by-products of the production
of NO using the NO synthase enzyme. Nitrites and ni-
trates are stable end products of the NO reaction with
molecular oxygen. The proportions of nitrates and ni-
trites are variable and cannot be accurately determined.
Therefore, the best indicator of NO production is the
sum of the nitrites and nitrates. The Cayman Chemical
kit used to determine nitrites and nitrates provides an
accurate and convenient method for measuring the total
concentrations through a simple two-step process. This
Table 2 Specific biochemistry tests
Inflammatory markers and endothelial dysfunction
• IL-1, IL-6, IL-8, IL-18
• TNF-α
• hsCRP and fibrinogen




• plasminogen activator inhibitor (PAI-1)
• fibrinogen
Renin Angiotensin Aldosterone System
• Ang II
• angiotensin converting enzyme (ACE)
• plasma renin activity
• serum aldosterone
Extracellular matrix and tissue inhibitors
• MMP-9
• TIMPs
IL interleukin, Ang II Angiotensin II, TNF-α tumor necrosis factor alpha,
hsCRP highly sensitive C-reactive protein, MMP metalloproteinase,
TIMPs tissue inhibitors of metalloproteinase
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test is based on the determination of nitrite, not of ni-
trate, using the Griess reaction. The method is very sim-
ple, and a large number of samples can be processed in
a short time, making it quite suitable for routine applica-
tion in research laboratories. Plasma samples, collected
in an EDTA anticoagulant, are first diluted four times
using distilled water and de-proteinized by adding 1/20
volume of zinc sulfate (300 g/L), giving a concentration
of 15 g/L. After centrifugation at 10,000 g for 5 min or
1000 g for 15 min at ambient temperature, 100 μL of
Griess reagent (1 g/L sulfanilamide, 25 g/L of phos-
phoric acid, and 0.1/L naphthylethylenediamine dihy-
drochloride) is added. After 10 min incubation at room
temperature, the sample develops a violet color, the
intensity of which is measured in a plate reader using a
540-nm wavelength [77]. Each sample will be tested in
duplicate. The determination of the standard curve of
nitrite concentration will be carried out using the proto-
col provided by the manufacturer. Subsequently, a graph
is drawn to map the intensity of readings at 540 nm to
known concentrations of nitrates or nitrites. The total
nitrate concentrations (nitrites + nitrates), or nitrates and
nitrites in isolation, are calculated by determining the
intersection of the spectrophotometer reading. The con-
centration of the sample is subsequently calculated by
the simple rule of three.
Thromboxane B2 will be evaluated in blood samples
collected in test tubes containing EDTA. The plasma is
separated by centrifugation and stored at −20 °C until test-
ing. The plasma samples are purified using a reversed-
phase column (Sep-Pak C18 - Waters Co., Milford, MA,
USA), and the TXB2 plasma levels (metabolite of TXA2)
are determined using a commercial enzyme immunoassay
kit (ELISA Cayman Chemical Co. Ann Arbor, MI, USA).
This assay uses 500 μL of venous blood plasma and is
based on the competition between TXB2 and a TXB2
tracer (TXB2 attached to an acetylcholinesterase mol-
ecule) with a limited number of TXB2-specific rabbit anti-
serum binding sites. The concentration of the tracer is
held constant, while the free TXB2 changes. The TXB2
antiserum complex (free tracer) binds to a rabbit mono-
clonal antibody previously attached to the plate, which is
rinsed to remove unwanted reagents, and Ellman’s reagent
is added (which contains the substrate for acetylcholin-
esterase). The product of this enzymatic reaction has a
yellow color and absorbs 420-nm wavelength light in a
spectrophotometer [78, 79].
Primary outcome measure
The primary outcome measure will be the change
from baseline in the peripheral blood pressure of
individuals with resistant hypertension after transcuta-
neous electrical nervous stimulation.
Secondary outcome measures
The secondary outcome measures from baseline are the
arterial stiffness measurement parameters (including
central blood pressure) of individuals with resistant
hypertension after transcutaneous electrical nervous
stimulation.
Assessment of outcomes
Blood pressure (mean of two measurements by an auto-
matic electronic device Omron HEM-711 DLX) and
hemodynamic parameters (by Omron HEM 9000 AI
device) will be measured in the office at the follow-up
visits.
Adverse events
The adverse events will be investigated by open ques-
tions and by a semistructured questionnaire, which will
address general symptoms and the presumed adverse ef-
fects of the electrostimulation used in the trial. Labora-
tory adverse events, such as metabolic changes and
inflammatory markers, will be investigated at the final
visit of the participants.
Missing or dropout
Participants will be registered with a phone number and




amostra.html was used to estimate the sample size. The
sample size calculation with a P alpha of 0.05, statistical
power of 80 %, standard deviation of 8 mmHg, and max-
imum acceptable absolute difference of 6 mmHg (dia-
stolic BP), indicated the necessity to study 28 patients
per group (intervention versus sham). However, consid-
ering a potential 10–15 % dropout or loss to follow-up
rate, 32 will be considered for each group. The differ-
ence of 5 mmHg (diastolic) has been achieved, on aver-
age, in clinical trials that have demonstrated the
advantage of a drug over placebo or other nonpharma-
cological treatment in the prevention of major cardio-
vascular outcomes.
Statistics
All analyses will be performed using SPSS Statistical
Software (IBM SPSS Statistics for Windows, Version
21.0. Armonk, NY, USA). Continuous variables will be
presented as mean ± SD, and categorical variables, as fre-
quencies. Differences between the groups at baseline will
be evaluated by an unpaired t test or the Mann–Whitney
test for comparison of continuous variables. The Chi-
square test or Fisher’s exact test will be employed to
compare categorical variables. The change from
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baseline to 4-week follow-up in the groups will be
evaluated using the paired t test for continuous vari-
ables. Pearson’s correlation will be used to assess the
relation between BP reduction and treatment (inter-
vention). For all analyses, a two-sided P < 0.05 will be
considered statistically significant.
Discussion
Over the decades, RH has become very common and
costly. Adequate control requires several drugs, and in
many cases, treatment is not successful. This is due to
target organ damage or even an autonomic imbalance.
Studies have shown that sympathetic nervous system in-
hibition by both renal denervation and by central inhib-
ition have significant effects in reducing BP; however,
these treatments are costly and invasive. Moreover, other
studies have shown that sympathetic nervous system
inhibition can also be noninvasively achieved by electric
current. Even so, the effects of electrical stimulation
on the metabolic system still need to be elucidated.
Additional file 2 shows the checklist of study protocol data
and related documents in accordance with SPIRIT (Stand-
ard Protocol Items: Recommendations for Interventional
Trials). The final report, and its extension to nonpharma-
cological interventions, will follow the main CONSORT
2010 guideline.
Trial status
The randomization of patients has begun.
Additional files
Additional file 1: Research Ethics Committee. Declaration of Research
Ethics Committee of the Medical School in São José do Rio Preto (FAMERP).
(PDF 182 kb)
Additional file 2: SPIRIT. Checklist of study protocol data and related
documents according to SPIRIT (Standard Protocol Items: Recommendations
for Interventional Trials). (PDF 105 kb)
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